Bioequivalence & Bioavailability International Journal,
Journal Year:
2024,
Volume and Issue:
8(1), P. 1 - 9
Published: Feb. 15, 2024
Researchers
are
increasingly
investigating
marketing
assertions
related
to
natural
products
and
supplements.
In
the
modern
era,
study
of
bioavailability
has
gained
prominence
as
a
burgeoning
scientific
discipline.
This
comprehensive
review
explores
in
pharmaceutical
applications,
shedding
light
on
their
intrinsic
challenges
innovative
strategies
for
improvement.
The
assessment
encompasses
limitations
including
poor
aqueous
solubility,
low
permeability,
instability,
which
collectively
impede
effective
absorption
human
body
hinder
utilization
these
compounds,
underscores
critical
need
enhanced
unlock
full
therapeutic
potential.
Such
have
spurred
research
into
approaches
overcome
optimize
bioavailability.
response
challenges,
this
highlights
cutting-edge
strategies,
nanoparticle
formulations,
lipid-based
delivery
systems,
prodrug
design,
means
enhance
These
aim
improve
stability,
overall
absorption,
thereby
maximizing
efficacy
formulations.
Moreover,
emphasizes
importance
understanding
interplay
between
formulation
techniques
physicochemical
properties
products.
By
integrating
approaches,
researchers
can
tailor
solutions
specific
providing
roadmap
overcoming
advancing
integration
mainstream
practice.
ACS Applied Bio Materials,
Journal Year:
2024,
Volume and Issue:
7(2), P. 692 - 710
Published: Feb. 6, 2024
In
order
to
improve
bioavailability,
stability,
control
release,
and
target
delivery
of
active
pharmaceutical
ingredients
(APIs),
as
well
mask
their
bitter
taste,
increase
efficacy,
minimize
side
effects,
a
variety
microencapsulation
(including
nanoencapsulation,
particle
size
<100
nm)
technologies
have
been
widely
used
in
the
industry.
Commonly
are
emulsion,
coacervation,
extrusion,
spray
drying,
freeze-drying,
molecular
inclusion,
microbubbles
microsponge,
fluidized
bed
coating,
supercritical
fluid
encapsulation,
electro
spinning/spray,
polymerization.
this
review,
APIs
categorized
by
complexity:
small
(compounds
with
low
weight,
like
Aspirin,
Ibuprofen,
Cannabidiol),
medium
weight
insulin,
peptides,
nucleic
acids),
living
microorganisms
(such
probiotics,
bacteria,
bacteriophages).
This
article
provides
an
overview
these
including
processes,
matrix,
recent
applications
APIs.
Furthermore,
advantages
disadvantages
common
terms
improving
efficacy
for
treatments
comprehensively
analyzed.
The
objective
is
summarize
most
progresses
on
enhancing
delivery,
masking
taste
thus
increasing
minimizing
effects.
At
end,
future
perspectives
highlighted.
Food Chemistry,
Journal Year:
2024,
Volume and Issue:
441, P. 138295 - 138295
Published: Jan. 3, 2024
This
study
evaluated
the
physicochemical
characteristics
of
nanostructured
lipid
carriers
(NLCs)
as
a
potential
vehicle
for
cannabidiol
(CBD),
lipophilic
molecule
with
great
to
promote
health
benefits.
NLCs
were
produced
using
hemp
seed
oil
and
fully-hydrogenated
soybean
at
different
proportions
emulsifiers
lecithin
(SL),
Tween
80
(T80)
mixture
SL:T80
(50:50).
CBD
was
tested
in
form
CBD-rich
extract
or
isolate
CBD,
verify
if
it
affects
characteristics.
Based
on
particle
size
polydispersity,
SL
considered
most
suitable
emulsifier
produce
NLCs.
All
had
no
remarkable
effect
NLCs,
resulting
CBD–loaded
below
250
nm,
high
entrapment
efficiency
retention
rate
100
%
30
days,
demonstrating
that
are
both
CBD.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 5, 2025
Cannabinoids
relieve
pain,
nausea,
anorexia
and
anxiety,
improve
quality
of
life
in
several
cancer
patients.
The
immunotherapy
with
checkpoint
inhibitors
(ICIs),
although
very
successful
a
subset
patients,
is
accompanied
by
moderate
to
severe
immune-related
adverse
events
(ir-AE)
that
often
necessitate
its
discontinuation.
Because
their
role
symptomatic
relief,
cannabinoids
have
been
used
combination
immune
inhibitor
(ICI)
immunotherapy.
A
few
studies
strongly
suggest
the
use
medicinal
cannabis
patients
attenuates
many
ir-AE
associated
ICI
increase
tolerability.
However,
no
significant
beneficial
effects
on
overall
survival,
progression
free
survival
or
relapses
were
observed;
rather,
some
noted
concurrent
administration
clinical
benefits
latter.
cannabinoids'
well
documented
immunosuppressive
mediated
through
cannabinoid
recptor-2
(CB2),
we
propose
considering
this
receptor
as
an
inhibitory
per
se.
simultaneous
neutralization
CB2,
treatment,
may
lead
better
outcomes
receiving
In
regard,
such
cannabidiol
(CBD)
cannabigerol
(CBG),
little
agonism
for
be
therapeutic
choices.
Additional
strategies
e.g.,
monoacylglycerol
lipase
(MAGL)
degrade
endocannabinoids
lipogenesis
formation
lipid
bilayers
cells
also
explored.
Future
should
take
into
consideration
gut
microbiota,
CYP450
polymorphism
haplotypes,
cannabinoid-drug
interactions
genetic
somatic
variations
occurring
receptors
signaling
pathways
personalized
cannabis-based
therapies
ICIs.
This
rational
knowledge-based
regimens
tailored
individual
Frontiers in Veterinary Science,
Journal Year:
2024,
Volume and Issue:
11
Published: April 25, 2024
Cannabidiol
(CBD)
is
a
natural
phytochemical
agent
and
one
of
the
most
abundant
found
in
Cannabis
sativa
.
It
known
to
exhibit
pharmacological
properties
on
various
condition
such
as
relieving-inflammation,
pain,
epilepsy,
anxiety
effect.
There
has
been
an
increasing
trend
globally
use
CBD
supplement
pets.
Consequently,
there
are
products
being
marketed
that
specifically
available
for
Veterinarians
pet
owners
concerned
following
ingestion,
different
formulations
may
result
level
circulating
blood
affect
safe
efficacy
Several
pharmacokinetics
studies
animals
have
mainly
conducted
with
oily
form
CBD.
To
date,
lack
data
regarding
direct
comparisons
among
plasma
kinetic
profiles
from
oral
administration
preparation
forms.
Therefore,
current
study
evaluated
compared
levels
single
using
four
preparations—liquid
(an
oil-based
form,
nanoemulsion
or
water-soluble
form)
semi-solid
(as
mixed
treat)
dogs.
In
total,
32
healthy,
crossbreed
dogs
were
randomly
assigned
into
4
groups
treated
according
1-period,
4-treatment
parallel-design.
The
three
liquid
forms
dosed
at
5
mg/kg
body
weight,
while
was
given
50
mg/treat/dog.
results
showed
profile
comparable
group.
nanoemulsion-based
tended
be
rapidly
absorbed
reached
its
peak
sooner
than
others.
However,
all
preparations
maximum
concentration
within
3
h
post-dose,
average
range
92–314
μg/L.
significant
differences
certain
parameters
between
This
first
provide
water
soluble,
nanoemulsion-based,
companion
animals.
should
facilitate
scrutiny
based
via
route
Pharmacopsychiatry,
Journal Year:
2024,
Volume and Issue:
57(03), P. 152 - 159
Published: Jan. 10, 2024
Abstract
Chronic
pain
is
primarily
conceptualized
as
a
disease
in
its
own
right
when
it
associated
with
emotional
distress
and
functional
impairment.
Pathophysiologically,
dysfunction
of
the
cortico-mesolimbic
connectome
major
importance,
overlapping
signals
nociceptive
stress
systems.
The
endocannabinoid
system
plays
an
important
role
central
processing
regulates
response.
Clinically,
there
moderate
evidence
that
cannabis-based
medicines
(CBM)
can
contribute
to
significant
reduction
pain,
especially
affect,
improvement
physical
function
sleep
quality
proportion
patients
chronic
pain.
analgesic
effect
appears
be
largely
independent
cause
In
this
context,
CBM
preferentially
stress-associated
processing.
